Diagnostic agent and therapeutic agent for pancreatic cancer
AssigneesPerseus Proteomics Inc., The University of Tokyo
InventorsHiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.
Claims29
A diagnostic drug for pancreatic cancer comprising an anti-AMIGO2 monoclonal antibody, wherein the anti-AMIGO2 monoclonal antibody is produced by at least one hybridoma cell line selected from the group consisting of a hybridoma cell line identified as PPMX0502 and deposited as FERM BP-10809, a hybridoma cell line identified as PPMX0504 and deposited as FERM BP-10810, a hybridoma cell line identified as PPMX0507 and deposited as FERM BP-10811, a hybridoma cell line identified as PPMX0508 and deposited as FERM BP-10812, and a hybridoma cell line identified as PPMX0519 and deposited as FERM BP-10813.
A therapeutic drug for pancreatic cancer comprising an anti-AMIGO2 monoclonal antibody and a pharmaceutically acceptable carrier, wherein the anti-AMIGO2 monoclonal antibody is produced by at least one hybridoma cell line selected from the group consisting of a hybridoma cell line identified as PPMX0502 and deposited as FERM BP-10809, a hybridoma cell line identified as PPMX0504 and deposited as FERM BP-10810, a hybridoma cell line identified as PPMX0507 and deposited as FERM BP-10811, a hybridoma cell line identified as PPMX0508 and deposited as FERM BP-10812, and a hybridoma cell line identified as PPMX0519 and deposited as FERM BP-10813.
A diagnostic kit comprising a diagnostic drug for pancreatic cancer, the diagnostic drug for pancreatic cancer comprising an anti-AMIGO2 monoclonal antibody, wherein the anti-AMIGO2 monoclonal antibody is produced by at least one hybridoma cell line selected from the group consisting of a hybridoma cell line identified as PPMX0502 and deposited as FERM BP-10809, a hybridoma cell line identified as PPMX0504 and deposited as FERM BP-10810, a hybridoma cell line identified as PPMX0507 and deposited as FERM BP-10811, a hybridoma cell line identified as PPMX0508 and deposited as FERM BP-10812, and a hybridoma cell line identified as PPMX0519 and deposited as FERM BP-10813.
Dependencies are inferred from the claim text.